CoChat

The simultaneous targeted Inhibition of ISG15 and HMGCR disrupts cancer stemness through metabolic collapse and induces synthetic lethality in pancreatic ductal adenocarcinoma

Open access
Sun, Jia, Wang, Jia-Mei, Zhang, Qi, Lin, Wen-Ying, Tang, Lin, Lu, Shi-Yang, Li, Bai-Qiang, Du, Zhen-Xian, Wang, Hua-Qin · 2025 · Journal of Experimental & Clinical Cancer Research

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Abstract

Precision oncology, a transformative paradigm in cancer therapeutics, leverages molecular profiling to design personalized interventions. Building on our prior discovery of ISG15’s role in pancreatic cancer stem cell (CSC) generation, we identified co-upregulation of ISG15 and HMGCR in pancreatic ductal adenocarcinoma (PDAC). Dual suppression of ISG15 and HMGCR triggered synthetic lethality, effectively eradicating CSCs and impairing tumor progression. To exploit this synergy, we engineered a hyaluronic acid-coated liposomal nanoplatform (LNP-Kd/Statin) for co-delivery of ISG15-targeting siRNA and HMGCR-inhibiting statins. Mechanistically, ISG15 directly interacts with HMGCR, and the knockdown of ISG15 stabilizes the HMGCR protein by inhibiting K48 ubiquitin-proteasomal degradation, a process that occurs independently of ISGylation, paradoxically elevating cholesterol levels to sustain cell survival while depleting metabolic intermediates, thereby inducing vulnerability. Sterolomics profiling confirmed this metabolic rewiring, linking cholesterol flux collapse to CSC elimination. Our findings not only elucidate a novel ISG15-HMGCR regulatory axis in PDAC pathogenesis but also establish a nanotechnology-enabled strategy to disrupt cancer stemness through metabolic targeting. This work advances the translational potential of synthetic lethality in precision oncology for aggressive malignancies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13046-025-03561-x

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Combined ISG15 Knockdown and Statin Treatment Induces Synthetic Lethality in Pancreatic Cancer Cells. (A-B) Drug sensitivity analysis of BxPC3 (A) and SW1990 (B) pancreatic cancer cells treated with drugs, following ISG15 knockdown (ISG15 KD) or control (Con) via CRISPR/Cas9-mediated gene editing. (C) Western blot validation of ISG15 protein knockdown efficiency in ISG15 KD vs. Con cells. (D) Schematic of colony formation assay: 200 single cells/well were treated with statins(20µM), ISG15 knockdown, or both. (E-F) Quantification of colony numbers in BxPC3 (E) and SW1990 (F) cells(n = 3 per group, unpaired two-tailed Student’s t test). (G) Spheroid formation in serum-free conditions following 10 days of assay. (H-I) Quantification of spheroid numbers in BxPC3 (H) and SW1990 (I) cells (n = 3 per group, unpaired two-tailed Student’s t test). Data are mean ± SD. *, P < 0.05; **, P < 0.01; ns, not significant
Fig. 1 Combined ISG15 Knockdown and Statin Treatment Induces Synthetic Lethality in Pancreatic Cancer Cells. (A-B) Drug sensitivity analysis of BxPC3 (A) and SW1990 (B) pancreatic cancer cells treated with drugs, following ISG15 knockdown (ISG15 KD) or control (Con) via CRISPR/Cas9-mediated gene editing. (C) Western blot validation of ISG15 protein knockdown efficiency in ISG15 KD vs. Con cells. (D) Schematic of colony formation assay: 200 single cells/well were treated with statins(20µM), ISG15 knockdown, or both. (E-F) Quantification of colony numbers in BxPC3 (E) and SW1990 (F) cells(n = 3 per group, unpaired two-tailed Student’s t test). (G) Spheroid formation in serum-free conditions following 10 days of assay. (H-I) Quantification of spheroid numbers in BxPC3 (H) and SW1990 (I) cells (n = 3 per group, unpaired two-tailed Student’s t test). Data are mean ± SD. *, P < 0.05; **, P < 0.01; ns, not significantCC BY · PubMed Central
Fig. 2 ISG15 Knockdown Stabilizes HMGCR Protein Expression in Pancreatic Cancer. (A) Immunohistochemistry (IHC) analysis of ISG15 and HMGCR protein expression in human pancreatic ductal adenocarcinoma (PDAC) tissue microarrays. High ISG15/HMGCR levels correlate with advanced tumor grades. (B-C) IHC (B) and immunofluorescence (IF) staining (C) of ISG15 and HMGCR in Kras/p53-driven murine PDAC (KPC) models, confirming co-upregulation but separate expression in malignant tissues. (D) qRT-PCR analysis of HMGCR mRNA levels in BxPC3 and SW1990 cells with ISG15 knockdown (KD) vs. control (Con) (n = 3 per group, one-way ANOVA followed by Tukey’s test). (E-F) Western blot (E) and quantification (F) of HMGCR protein levels in ISG15 KD cells, demonstrating post-translational stabilization (n = 3 per group, one-way ANOVA followed by Tukey’s test). The experiments were performed at least three times. Data are mean ± SD. *, P < 0.05; **, P < 0.01; ns, not significant
Fig. 2 ISG15 Knockdown Stabilizes HMGCR Protein Expression in Pancreatic Cancer. (A) Immunohistochemistry (IHC) analysis of ISG15 and HMGCR protein expression in human pancreatic ductal adenocarcinoma (PDAC) tissue microarrays. High ISG15/HMGCR levels correlate with advanced tumor grades. (B-C) IHC (B) and immunofluorescence (IF) staining (C) of ISG15 and HMGCR in Kras/p53-driven murine PDAC (KPC) models, confirming co-upregulation but separate expression in malignant tissues. (D) qRT-PCR analysis of HMGCR mRNA levels in BxPC3 and SW1990 cells with ISG15 knockdown (KD) vs. control (Con) (n = 3 per group, one-way ANOVA followed by Tukey’s test). (E-F) Western blot (E) and quantification (F) of HMGCR protein levels in ISG15 KD cells, demonstrating post-translational stabilization (n = 3 per group, one-way ANOVA followed by Tukey’s test). The experiments were performed at least three times. Data are mean ± SD. *, P < 0.05; **, P < 0.01; ns, not significantCC BY · PubMed Central
Fig. 3 ISG15 Depletion Stabilizes HMGCR Protein by Impeding Ubiquitin-Proteasomal Degradation independently of its ISGylation. (A) The binding of ISG15 to HMGCR by molecular docking. (B-C) CO-IP was used to detect the direct interaction between ISG15 and HMGCR protein. (D-E) The knocked down ISG15 cells overexpressing ISG15 wild-type and mutant plasmids(G156/157A), and detected the expression of HMGCR protein in Western blot after transfection of BxPC3 and SW1990 cells for 24 h. (F) Western blot analysis of HMGCR protein stability in ISG15 knockdown (KD) and control (Con) BxPC3 and SW1990 cells treated with cycloheximide (CHX) to block new protein synthesis. (G-H) Quantification of HMGCR protein half-life (t₁/₂) in BxPC3 (G) and SW1990 (H) cells, demonstrating prolonged stability in ISG15 KD cells (n = 3 per group, two-way ANOVA with Sidak’s multiple comparisons test). (I) Western blot analysis of HMGCR levels in ISG15 KD cells treated with MG132 (proteasome inhibitor) or E64D/Pepstatin A (autophagy-lysosome inhibitor). (J-K) Quantification of HMGCR protein levels in BxPC3 (J) and SW1990 (K) cells under proteostatic inhibition. MG132 abolished HMGCR accumulation in ISG15 KD cells, confirming proteasome-dependent degradation (n = 3 per group, unpaired two-tailed Student’s t test). (L-N) Western blot was used to detect the HMGCR of ubiquitination level (L), K48 ubiquitin level (M) and K63 ubiquitin (N) level in ISG15 knockdown BxPC3 and SW1990 cells. The experiments were performed at least three times. Data are mean ± SD, significance determined unpaired Student’s t test or one-way ANOVA followed by Tukey’s test. *, P < 0.05; **, P < 0.01; ns, not significant
Fig. 3 ISG15 Depletion Stabilizes HMGCR Protein by Impeding Ubiquitin-Proteasomal Degradation independently of its ISGylation. (A) The binding of ISG15 to HMGCR by molecular docking. (B-C) CO-IP was used to detect the direct interaction between ISG15 and HMGCR protein. (D-E) The knocked down ISG15 cells overexpressing ISG15 wild-type and mutant plasmids(G156/157A), and detected the expression of HMGCR protein in Western blot after transfection of BxPC3 and SW1990 cells for 24 h. (F) Western blot analysis of HMGCR protein stability in ISG15 knockdown (KD) and control (Con) BxPC3 and SW1990 cells treated with cycloheximide (CHX) to block new protein synthesis. (G-H) Quantification of HMGCR protein half-life (t₁/₂) in BxPC3 (G) and SW1990 (H) cells, demonstrating prolonged stability in ISG15 KD cells (n = 3 per group, two-way ANOVA with Sidak’s multiple comparisons test). (I) Western blot analysis of HMGCR levels in ISG15 KD cells treated with MG132 (proteasome inhibitor) or E64D/Pepstatin A (autophagy-lysosome inhibitor). (J-K) Quantification of HMGCR protein levels in BxPC3 (J) and SW1990 (K) cells under proteostatic inhibition. MG132 abolished HMGCR accumulation in ISG15 KD cells, confirming proteasome-dependent degradation (n = 3 per group, unpaired two-tailed Student’s t test). (L-N) Western blot was used to detect the HMGCR of ubiquitination level (L), K48 ubiquitin level (M) and K63 ubiquitin (N) level in ISG15 knockdown BxPC3 and SW1990 cells. The experiments were performed at least three times. Data are mean ± SD, significance determined unpaired Student’s t test or one-way ANOVA followed by Tukey’s test. *, P < 0.05; **, P < 0.01; ns, not significantCC BY · PubMed Central
Fig. 4 ISG15 Knockdown Rewires Cholesterol Metabolism, Inducing a Metabolic Vulnerability in Pancreatic Cancer. (A) Principal component analysis (PCA) of sterolomics profiles in control (Con, Group A) and ISG15 knockdown (KD, Group B) pancreatic cancer cells. The 95% confidence ellipse confirms distinct metabolic clustering (Dim-1: 46.6%; Dim-2: 28.9%; cumulative variance: 76%) (n = 4 per group). (B) Loading plot highlighting the top 10 lipids driving PCA separation, dominated by cholesterol biosynthesis intermediates. (C) Heatmap of cholesterol-related metabolites, showing global lipid depletion but paradoxical cholesterol accumulation (red) in ISG15 KD cells (hypothesis test, SQUALENE-2,3-EPOXIDE, P = 0.036551699; LANOSTEROL, P = 0.042861789; LATHOSTEROL, P = 0.024469078; CHOLESTEROL, P = 0.034967532; DESMOSTEROL/DEHYDROCHOLESTEROL, P = 0.0000495; ZYMOSTEROL, P = 0.0000000146; DEHYDROLATHOSTEROL, P = 0.008821069). (D) Volcano plot identifying differentially abundant metabolites (|log ~ 2 ~ FC| >1, P < 0.05) (n = 4 per group, Mann-Whitney U test). (E) Box plots of the top 4 downregulated cholesterol precursors: desmosterol/dehydrocholesterol, squalene-2,3-epoxide, zymosterol, lathosterol, and also the cholesterol (n = 4 per group, unpaired Student’s t test). Each sample was run in 3 technical replicates. Data are mean ± SD. *, P < 0.05; **, P < 0.01; ns, not significant
Fig. 4 ISG15 Knockdown Rewires Cholesterol Metabolism, Inducing a Metabolic Vulnerability in Pancreatic Cancer. (A) Principal component analysis (PCA) of sterolomics profiles in control (Con, Group A) and ISG15 knockdown (KD, Group B) pancreatic cancer cells. The 95% confidence ellipse confirms distinct metabolic clustering (Dim-1: 46.6%; Dim-2: 28.9%; cumulative variance: 76%) (n = 4 per group). (B) Loading plot highlighting the top 10 lipids driving PCA separation, dominated by cholesterol biosynthesis intermediates. (C) Heatmap of cholesterol-related metabolites, showing global lipid depletion but paradoxical cholesterol accumulation (red) in ISG15 KD cells (hypothesis test, SQUALENE-2,3-EPOXIDE, P = 0.036551699; LANOSTEROL, P = 0.042861789; LATHOSTEROL, P = 0.024469078; CHOLESTEROL, P = 0.034967532; DESMOSTEROL/DEHYDROCHOLESTEROL, P = 0.0000495; ZYMOSTEROL, P = 0.0000000146; DEHYDROLATHOSTEROL, P = 0.008821069). (D) Volcano plot identifying differentially abundant metabolites (|log ~ 2 ~ FC| >1, P < 0.05) (n = 4 per group, Mann-Whitney U test). (E) Box plots of the top 4 downregulated cholesterol precursors: desmosterol/dehydrocholesterol, squalene-2,3-epoxide, zymosterol, lathosterol, and also the cholesterol (n = 4 per group, unpaired Student’s t test). Each sample was run in 3 technical replicates. Data are mean ± SD. *, P < 0.05; **, P < 0.01; ns, not significantCC BY · PubMed Central
Fig. 5 Engineering and Characterization of the HA-Coated LNP-Kd/Statin. (A) Nanoplatform Schematic illustration of LNP-Kd/Statin synthesis: Hyaluronic acid (HA)-modified liposomes (LNP-Statin) were functionalized with ISG15-targeting siRNA plasmids via electrostatic interactions, yielding the dual-loaded LNP-Kd/Statin. (B) Transmission electron microscopy (TEM) images confirming spherical morphology, with a core diameter of 120.7 ± 9.0 nm. Dynamic light scattering (DLS) revealed a hydrodynamic size of 197.7 ± 9.3 nm, reflecting hydration effects. (C) Zeta potential analysis: LNP-Kd/Statin exhibited a surface charge of + 33.23 ± 0.96 mV, reduced from + 43.83 ± 1.01 mV in LNP-Statin due to siRNA neutralization. (D) Encapsulation efficiency (EE) and drug loading (DL) for statins (EE: ; DL: ) and siRNA (EE: ~100%; DL: 1.25%). (E) Sustained siRNA release profile over 72 h under physiological conditions. (F) Confocal microscopy of Dil-labeled LNP-Kd/Statin (red) internalized by BxPC3 cells (nuclei: blue, DAPI; scale bar: 20 μm). Each sample was run in 3 technical replicates. Data are mean ± SD, significance determined unpaired Student’s t test. *, P < 0.05; **, P < 0.01; ns, not significant
Fig. 5 Engineering and Characterization of the HA-Coated LNP-Kd/Statin. (A) Nanoplatform Schematic illustration of LNP-Kd/Statin synthesis: Hyaluronic acid (HA)-modified liposomes (LNP-Statin) were functionalized with ISG15-targeting siRNA plasmids via electrostatic interactions, yielding the dual-loaded LNP-Kd/Statin. (B) Transmission electron microscopy (TEM) images confirming spherical morphology, with a core diameter of 120.7 ± 9.0 nm. Dynamic light scattering (DLS) revealed a hydrodynamic size of 197.7 ± 9.3 nm, reflecting hydration effects. (C) Zeta potential analysis: LNP-Kd/Statin exhibited a surface charge of + 33.23 ± 0.96 mV, reduced from + 43.83 ± 1.01 mV in LNP-Statin due to siRNA neutralization. (D) Encapsulation efficiency (EE) and drug loading (DL) for statins (EE: ; DL: ) and siRNA (EE: ~100%; DL: 1.25%). (E) Sustained siRNA release profile over 72 h under physiological conditions. (F) Confocal microscopy of Dil-labeled LNP-Kd/Statin (red) internalized by BxPC3 cells (nuclei: blue, DAPI; scale bar: 20 μm). Each sample was run in 3 technical replicates. Data are mean ± SD, significance determined unpaired Student’s t test. *, P < 0.05; **, P < 0.01; ns, not significantCC BY · PubMed Central
Fig. 6 LNP-Kd/Statin Nanotherapy Suppresses Pancreatic Cancer Organoids and Xenografts via Dual Targeting of ISG15 and HMGCR. (A) Growth kinetics of BxPC3-derived pancreatic cancer organoids treated with control (Con), ISG15 knockdown (KD), statin monotherapy (Statin), or LNP-Kd/Statin combination, monitored at days 3, 7, and 10 post-treatment. (B) Hematoxylin and eosin (H&E) staining of organoids at day 10, showing disrupted architecture in the combination group (scale bars: 100 μm). (C) Immunofluorescence staining confirming ISG15 (green) and HMGCR (red) suppression in LNP-Kd/Statin-treated organoids (nuclei: blue, DAPI; scale bars: 50 μm). (D) In vivo therapeutic schema: Nude mice bearing BxPC3 xenografts received tail vein injections of nanotherapeutics starting at day 10 post-implantation. Tumors were harvested at day 28 (n = 5 per group). (E) Tumor weights across treatment groups (n = 5 per group, one-way ANOVA with Tukey’s multiple comparisons test). (F) Mouse body weight changes, indicating no systemic toxicity (n = 5 per group, one-way ANOVA with Tukey’s multiple comparisons test). (G) Immunofluorescence staining of Ki-67 in LNP-Kd/Statin-treated and control groups (n = 5 per group, one-way ANOVA with Tukey’s multiple comparisons test). (H) Quantification of the positive cell rate of Ki-67 in xenograft tumors (n = 5 per group, one-way ANOVA with Tukey’s multiple comparisons test). Data are mean ± SD. *, P < 0.05; **, P < 0.01; ns, not significant
Fig. 6 LNP-Kd/Statin Nanotherapy Suppresses Pancreatic Cancer Organoids and Xenografts via Dual Targeting of ISG15 and HMGCR. (A) Growth kinetics of BxPC3-derived pancreatic cancer organoids treated with control (Con), ISG15 knockdown (KD), statin monotherapy (Statin), or LNP-Kd/Statin combination, monitored at days 3, 7, and 10 post-treatment. (B) Hematoxylin and eosin (H&E) staining of organoids at day 10, showing disrupted architecture in the combination group (scale bars: 100 μm). (C) Immunofluorescence staining confirming ISG15 (green) and HMGCR (red) suppression in LNP-Kd/Statin-treated organoids (nuclei: blue, DAPI; scale bars: 50 μm). (D) In vivo therapeutic schema: Nude mice bearing BxPC3 xenografts received tail vein injections of nanotherapeutics starting at day 10 post-implantation. Tumors were harvested at day 28 (n = 5 per group). (E) Tumor weights across treatment groups (n = 5 per group, one-way ANOVA with Tukey’s multiple comparisons test). (F) Mouse body weight changes, indicating no systemic toxicity (n = 5 per group, one-way ANOVA with Tukey’s multiple comparisons test). (G) Immunofluorescence staining of Ki-67 in LNP-Kd/Statin-treated and control groups (n = 5 per group, one-way ANOVA with Tukey’s multiple comparisons test). (H) Quantification of the positive cell rate of Ki-67 in xenograft tumors (n = 5 per group, one-way ANOVA with Tukey’s multiple comparisons test). Data are mean ± SD. *, P < 0.05; **, P < 0.01; ns, not significantCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Research works printed but not linked: 1

  1. Park W, Chawla A, O’Reilly EM. Pancreatic Cancer: Rev JAMA. 2021;326(9):851–62.

Cited by

See all 7

Metadata

Authors
Sun, J., Wang, J.-M., Zhang, Q., Lin, W.-Y., Tang, L., Lu, S.-Y., Li, B.-Q., Du, Z.-X., & Wang, H.-Q.
Affiliations
  • Nanjing University of Chinese Medicine (CN)
  • Criminal Investigation Police University of China (CN)
  • First Hospital of China Medical University (CN)
  • China Medical University (CN)
Corresponding author
  • Du, Zhen-Xian
  • Wang, Hua-Qin
Venue
Journal of Experimental & Clinical Cancer Research
Published
2025-12-09
Volume
44
Issue
1
Pages
317-317
ISSN
  • 0392-9078 (ISSN-L)
  • 1756-9966
OpenAlex
W4417230833
Cited by
5
References
36
Citations by year
2026: 5
FWCI
2.25
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Experimental & Clinical Cancer Research (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (82203337)
  • Natural Science Foundation of Liaoning Province (2024-MSLH-542, 2023JH2/20200160)
  • Applied Basic Research Program (2023JH2/101600012)
  • Liaoning Province Central Guidance Local Science and Technology Development Fund Plan (2024JH6/100800018)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
ISG15, HMGCR, pancreatic ductal adenocarcinoma, cancer stem cells, synthetic lethality, cholesterol metabolism, K48-linked ubiquitination, protein stability, siRNA delivery, statins, metabolic targeting, precision oncology
MeSH terms
Synthetic Lethal Mutations, Animals, Humans, Hydroxymethylglutaryl CoA Reductases, Pancreatic Neoplasms, Neoplastic Stem Cells, Ubiquitins, Cytokines, Carcinoma, Pancreatic Ductal, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The simultaneous targeted Inhibition of ISG15 and HMGCR disrupts cancer stemness through metabolic collapse and induces synthetic lethality in pancreatic ductal adenocarcinoma. https://app.cochat.ai/papers/10.1186/s13046-025-03561-x
The paper
Sun, J., Wang, J.-M., Zhang, Q., Lin, W.-Y., Tang, L., Lu, S.-Y., Li, B.-Q., Du, Z.-X., & Wang, H.-Q. (2025). The simultaneous targeted Inhibition of ISG15 and HMGCR disrupts cancer stemness through metabolic collapse and induces synthetic lethality in pancreatic ductal adenocarcinoma. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-025-03561-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.